The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource.

ABSTRACT:

Background

The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated tissue microarrays (TMA) from prostate cancer samples obtained from multiple institutions across several global locations.

Methods

Three separate TMA sets were built that differ by purpose and disease state.

Results

The intended use of TMA1 (Primary Matched LN) is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to letha

SUBMITTER: Ouellet V 

PROVIDER: S-EPMC9381093 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature